Precision BioSciences (NASDAQ:DTIL) vs. Regeneron Pharmaceuticals (NASDAQ:REGN) Head to Head Contrast

Precision BioSciences (NASDAQ:DTIL) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, risk, profitability, earnings, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares Precision BioSciences and Regeneron Pharmaceuticals”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Precision BioSciences	$34.26 million	5.78	-$45.72 million	($2.80)	-2.56
Regeneron Pharmaceuticals	$14.34 billion	5.71	$4.50 billion	$40.46	19.67

Regeneron Pharmaceuticals has higher revenue and earnings than Precision BioSciences. Precision BioSciences is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Precision BioSciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.2, suggesting that its share price is 80% less volatile than the S&P 500.

Profitability

This table compares Precision BioSciences and Regeneron Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Precision BioSciences	-96.73%	-72.52%	-32.25%
Regeneron Pharmaceuticals	27.86%	13.47%	10.34%

Analyst Ratings

This is a summary of current ratings and price targets for Precision BioSciences and Regeneron Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Precision BioSciences	1	0	4	0	2.60
Regeneron Pharmaceuticals	0	10	14	0	2.58

Precision BioSciences presently has a consensus target price of $32.25, suggesting a potential upside of 349.79%. Regeneron Pharmaceuticals has a consensus target price of $802.18, suggesting a potential upside of 0.79%. Given Precision BioSciences’ stronger consensus rating and higher possible upside, equities research analysts clearly believe Precision BioSciences is more favorable than Regeneron Pharmaceuticals.

Insider & Institutional Ownership

38.0% of Precision BioSciences shares are held by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are held by institutional investors. 2.7% of Precision BioSciences shares are held by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Regeneron Pharmaceuticals beats Precision BioSciences on 10 of the 14 factors compared between the two stocks.

About Precision BioSciences

Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.